Wang R, Li Z, Liu S, Zhang D (2023) Global, regional and national burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019: a systematic analysis based on the Global Burden of Disease Study 2019. BMJ Open 13(3):e065186. https://doi.org/10.1136/bmjopen-2022-065186

Article  PubMed  PubMed Central  Google Scholar 

Friedman S, Blumberg RS (2012) Inflammatory bowel disease. In Harrison’s Principles of Internal Medicine (pp. 2477–2495). McGraw Hill. https://accessmedicine.mhmedical.com/content.aspx?bookid=2129§ionid=192282500

Google Scholar 

Veauthier B, Hornecker JR (2018) Crohn’s disease: diagnosis and management. Am Fam Physician 98(11):661–669

PubMed  Google Scholar 

Ghosh N, Premchand P (2015) A UK cost of care model for inflammatory bowel disease. Frontline Gastroenterol 6(3):169–174. https://doi.org/10.1136/flgastro-2014-100514

Article  PubMed  PubMed Central  Google Scholar 

Feuerstein JD, Cheifetz AS (2017) Crohn disease: epidemiology, diagnosis, and management. Mayo Clin Proc 92(7):1088–1103. https://doi.org/10.1016/j.mayocp.2017.04.010

Article  CAS  PubMed  Google Scholar 

Lahat A, Lang A, Ben-Horin S (2012) Impact of cannabis treatment on the quality of life, weight and clinical disease activity in inflammatory bowel disease patients: a pilot prospective study. Digestion 85:1–8

Article  PubMed  Google Scholar 

Papamichael K, Lin S, Moore M et al (2019) Infliximab in inflammatory bowel disease. Ther Adv Chronic Dis 26(10):2040622319838443. https://doi.org/10.1177/2040622319838443

Article  CAS  Google Scholar 

Storr MA, Keenan CM, Zhang H et al (2009) Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis. Inflamm Bowel Dis 15(11):1678–1685. https://doi.org/10.1002/ibd.20960

Article  PubMed  Google Scholar 

Hasenoehrl C, Taschler U, Storr M, Schicho R (2016) The gastrointestinal tract – a central organ of cannabinoid signaling in health and disease. J Neurogastroenterol Motility 28(12):1765–1780

Article  CAS  Google Scholar 

Vianna CR, Donato J, Rossi J et al (2012) Cannabinoid receptor 1 in the vagus nerve is dispensable for body weight homeostasis but required for normal gastrointestinal motility. J Neurosci 32(30):10331–10337

Article  CAS  PubMed  PubMed Central  Google Scholar 

Naftali T, Mechulam R, Lev LB, Konikoff FM (2014) Cannabis for inflammatory bowel disease. Dig Dis 32(4):468–474. https://doi.org/10.1159/000358155

Article  PubMed  Google Scholar 

Jamontt JM, Molleman A, Pertwee RG, Parsons ME (2010) The effects of delta-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis. Br J Pharmacol 160(3):712–723. https://doi.org/10.1111/j.1476-5381.2010.00791.x

Article  CAS  PubMed  PubMed Central  Google Scholar 

Doeve BH, van de Meeberg MM, van Schaik FDM, Fidder HH (2021) A systematic review with meta-analysis of the efficacy of cannabis and cannabinoids for inflammatory bowel disease: what can we learn from randomized and nonrandomized studies? J Clin Gastroenterol 55(9):798–809. https://doi.org/10.1097/MCG.0000000000001393

Article  PubMed  Google Scholar 

Alhouayek M, Muccioli GG (2012) The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity. Trends Mol Med 18(10):615–625. https://doi.org/10.1016/j.molmed.2012.07.009

Article  CAS  PubMed  Google Scholar 

Haroutounian S, Arendt-Nielsen L, Belton J et al (2021) International association for the study of pain presidential task force on cannabis and cannabinoid analgesia: research agenda on the use of cannabinoids, cannabis, and cannabis-based medicines for pain management. Pain 162(Suppl 1):S117–S124. https://doi.org/10.1097/j.pain.0000000000002266

Article  PubMed  PubMed Central  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. British Med J 372(71):n71. https://doi.org/10.1136/bmj.n71

Article  Google Scholar 

Sterne JAC, Savović J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https://doi.org/10.1136/bmj.l4898

Article  PubMed  Google Scholar 

Guyatt GH, Oxman AD, Vist GE et al (2008) GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336:924–926

Article  PubMed  PubMed Central  Google Scholar 

Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557–560

Article  PubMed  PubMed Central  Google Scholar 

Naftali T, Bar-Lev Schleider L, Dotan I et al (2013) Cannabis induces a clinical response in patients with Crohn’s disease: a prospective placebo-controlled study. Clin Gastroenterol Hepatol 11(10):1276-1280.e1. https://doi.org/10.1016/j.cgh.2013.04.034

Article  CAS  PubMed  Google Scholar 

Naftali T, Schlieder LBL, Konikoff FM (2017) The effect of cannabis on Crohn’s disease patients. International Association of Cannabis Medicine (IACM), Berlin, Germany

Google Scholar 

Naftali T, Mechulam R, Marii A et al (2017) Low-dose cannabidiol is safe but not effective in the treatment for Crohn’s disease, a randomized controlled trial. Dig Dis Sci 62(6):1615–1620. https://doi.org/10.1007/s10620-017-4540-z

Article  CAS  PubMed  Google Scholar 

Naftali T, Bar-Lev Schleider L, Almog S et al (2021) Oral CBD-rich cannabis induces clinical but not endoscopic response in patients with Crohn’s disease, a randomised controlled trial. J Crohns Colitis 15(11):1799–1806. https://doi.org/10.1093/ecco-jcc/jjab069

Article  PubMed  Google Scholar 

TartakoverMatalon S, Azar S, Meiri D et al (2021) Endocannabinoid levels in ulcerative colitis patients correlate with clinical parameters and are affected by cannabis consumption. Front Endocrinol (Lausanne) 12:685289. https://doi.org/10.3389/fendo.2021.685289

Article  Google Scholar 

Aspis I, Feingold D, Weiser M et al (2015) Cannabis use and mental health-related quality of life among individuals with depressive disorders. Psychiatry Res 230(2):341–349

Article  PubMed  Google Scholar 

Cohen K, Weizman A, Weinstein A (2019) Positive and negative effects of cannabis and cannabinoids on health. Clin Pharmacol Therapeutics 105(5):1139–47

Article  Google Scholar 

Fortin D, Massin S (2020) Medical cannabis: thinking out of the box of the healthcare system. Journal de gestion et d’économie de la santé 2:110–118. https://doi.org/10.3917/jges.202.0110

Article  Google Scholar 

Sakurai T, Saruta M (2022) Positioning and usefulness of biomarkers in inflammatory bowel disease. Digestion 104(1):30–41

Article  PubMed  Google Scholar 

Chen P, Zhou G, Lin J et al (2020) Serum biomarkers for inflammatory bowel disease. Front Med 22:7

CAS  Google Scholar 

Zhu J, Zhu N, Wang J et al (2024) Monocyte CD36 expression predicts disease activity in patients with Crohn’s disease. Gastroenterol Res Pract 2024:9202686. [Internet]. Available from: https://pubmed.ncbi.nlm.nih.gov/39524404/. Accessed 1 Nov 2024

Kennedy NA, Jones GR, Plevris N et al (2019) Association between level of fecal calprotectin and progression of Crohn’s disease. Clin Gastroenterol Hepatol 17(11):2269-2276.e4

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alghoul Z, Yang C, Merlin D (2022) The current status of molecular biomarkers for inflammatory bowel disease. Biomed 10(7):1492. [Internet]. [cited 2022 Oct 23]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9312796/